Pay in 4 interest-free payments of $5.27 Learn more
Ships within 48 hours · Estimated delivery Sep 2 - Sep 7
What licensed weight-loss treatments are available in the UK instead
raises IGF-1 and carries glucose-tolerance risk Compound Semaglutide (Wegovy) Class GLP-1 receptor agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs
Keep a record of daily doses and injection site rotation for consistency
For some, this can be a more comfortable option with less potential for soreness at the injection site
No IGF-1 or Growth Hormone Receptor Activation Full-length growth hormone produces complex metabolic effects including appetite stimulation through IGF-1 (insulin-like growth factor-1) production and direct growth hormone receptor activation
